-

Triplet Therapeutics to Present at Cowen 40th Annual Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Triplet Therapeutics, Inc., a biotechnology company harnessing new insights from human genetics to develop transformative treatments for repeat expansion disorders, today announced that Nessan Bermingham, Ph.D., Triplet’s co-founder, president and chief executive officer, will present at the Cowen and Company 40th Annual Health Care Conference taking place in Boston March 2-4, 2020.

Dr. Bermingham will provide an overview of Triplet’s approach and recent progress to develop transformative treatments for repeat expansion disorders, a group of more than 40 known genetic diseases including Huntington’s disease, spinocerebellar ataxias and myotonic dystrophy. A significant body of human genetic evidence has identified one central pathway, known as the DNA damage response (DDR) pathway, that drives onset and progression across many of these disorders. Triplet is developing antisense oligonucleotide (ASO) and small interfering RNA (siRNA) therapeutics to precisely modulate the DDR mechanism that drives repeat expansion and has the potential to address repeat expansion disorders en masse.

Dr. Bermingham’s presentation details are as follows:

Date: Tuesday, March 3
Time: 2:00 - 2:25 p.m.
Location: Boston Marriott Copley Place

About Triplet Therapeutics

Triplet Therapeutics is a biotechnology company harnessing new insights from human genetics to develop transformative treatments for patients with unmet medical needs to target the underlying cause of repeat expansion disorders, a group of more than 40 known genetic diseases including Huntington’s disease, spinocerebellar ataxias and myotonic dystrophy. Triplet was founded by Nessan Bermingham, Ph.D., Atlas Venture and Andrew Fraley, Ph.D. Triplet has raised $59 million in funding to date, including its Series A funding in 2019 led by MPM Capital and Pfizer Ventures, with Atlas Venture, Invus, Partners Innovation Fund and Alexandria Venture Investments participating. Triplet is headquartered in Cambridge, Mass. For more information, please visit www.triplettx.com.

Contacts

Mary Carmichael
Ten Bridge Communications
mary@tenbridgecommunications.com
617-413-3543

Triplet Therapeutics, Inc.


Release Summary
Triplet Therapeutics to present at the Cowen and Company 40th Annual Health Care Conference on Tuesday, March 3.
Release Versions

Contacts

Mary Carmichael
Ten Bridge Communications
mary@tenbridgecommunications.com
617-413-3543

More News From Triplet Therapeutics, Inc.

Triplet Therapeutics Presents Preclinical Data for TTX-3360, Announces Equity Pledge at the CHDI Foundation’s 16th Annual HD Therapeutics Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Triplet Therapeutics, Inc., a biotechnology company leveraging insights from the human genetics of repeat expansion disorders (REDs), today presented preclinical data in Huntington’s disease (HD) for its first clinical candidate TTX-3360, including the therapeutic target and route of administration, in a virtual presentation at the CHDI Foundation’s 16th Annual HD Therapeutics Conference. Also in the presentation, Triplet underscored its long-term commitment t...

Triplet Therapeutics to Present at Upcoming Events

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Triplet Therapeutics, Inc., a biotechnology company leveraging insights from the human genetics of repeat expansion disorders (REDs), today announced that Nessan Bermingham, Ph.D., Triplet’s chief executive officer, president and founder, will present at the following upcoming virtual events: Stifel 2021 CNS Day, Thursday, April 1, 2021 fireside chat at 2:00 p.m. ET; Guggenheim Healthcare Talks 2021 | Genomic Medicines & Rare Disease, Thursday, April 1, 20...

Triplet Therapeutics Appoints Kathy Biberstein, J.D., and Stephen Webster to its Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Triplet Therapeutics, Inc., a biotechnology company leveraging insights from the human genetics of repeat expansion disorders (REDs), today announced the appointments of Kathy Biberstein, J.D., and Stephen Webster to its board of directors. Ms. Biberstein brings extensive legal, policy and operations expertise in the global biopharma industry, most recently serving as Executive Vice President, Chief Administrative & Legal Officer, Chief Compliance & Ri...
Back to Newsroom